NEW YORK , June 29, 2026 /PRNewswire/ --
NEW YORK , June 24, 2026 /PRNewswire/ --
NEW YORK , June 19, 2026 /PRNewswire/ --
NEW YORK , June 14, 2026 /PRNewswire/ --
Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion...
Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approval On track for expected CRL response submission...
NEW YORK , June 8, 2026 /PRNewswire/ --
NEW YORK , June 3, 2026 /PRNewswire/ --
Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor...
The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision Bitopertin, an oral glycine...